Cargando…

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

BACKGROUND: There is an urgent need for novel, noninvasive biomarkers to diagnose Alzheimer’s disease (AD) in the predementia stages and to predict the rate of decline. Therefore, we set up the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery (EMIF-AD MBD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bos, Isabelle, Vos, Stephanie, Vandenberghe, Rik, Scheltens, Philip, Engelborghs, Sebastiaan, Frisoni, Giovanni, Molinuevo, José Luis, Wallin, Anders, Lleó, Alberto, Popp, Julius, Martinez-Lage, Pablo, Baird, Alison, Dobson, Richard, Legido-Quigley, Cristina, Sleegers, Kristel, Van Broeckhoven, Christine, Bertram, Lars, ten Kate, Mara, Barkhof, Frederik, Zetterberg, Henrik, Lovestone, Simon, Streffer, Johannes, Visser, Pieter Jelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035398/ https://www.ncbi.nlm.nih.gov/pubmed/29980228 http://dx.doi.org/10.1186/s13195-018-0396-5

Ejemplares similares

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
por: ten Kate, Mara, et al.
Publicado: (2018)

Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
por: Hong, Shengjun, et al.
Publicado: (2020)

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
por: Westwood, Sarah, et al.
Publicado: (2020)

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
por: Shi, Liu, et al.
Publicado: (2021)

Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks
por: Zhang, Yuting, et al.
Publicado: (2022)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
por: Neumann, Alexander, et al.
Publicado: (2022)

Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
por: Homann, Jan, et al.
Publicado: (2022)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023)

Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019)

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
por: Stamate, Daniel, et al.
Publicado: (2019)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
por: Kim, Min, et al.
Publicado: (2019)

Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
por: Xu, Jin, et al.
Publicado: (2021)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019)

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
por: Konijnenberg, Elles, et al.
Publicado: (2020)

The EMIF-AD PreclinAD study: study design and baseline cohort overview
por: Konijnenberg, Elles, et al.
Publicado: (2018)

Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study
por: Legdeur, Nienke, et al.
Publicado: (2018)

Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations
por: Bettens, Karolien, et al.
Publicado: (2015)

An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease
por: De Roeck, Arne, et al.
Publicado: (2018)

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology
por: Shi, Liu, et al.
Publicado: (2020)

Is the association between blood pressure and cognition in the oldest-old modified by physical, vascular or brain pathology markers? The EMIF-AD 90 + Study
por: Legdeur, Nienke, et al.
Publicado: (2023)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Magnetoencephalography Brain Signatures Relate to Cognition and Cognitive Reserve in the Oldest-Old: The EMIF-AD 90 + Study
por: Griffa, Alessandra, et al.
Publicado: (2021)

TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort
por: van der Zee, Julie, et al.
Publicado: (2011)

Current status on Alzheimer disease molecular genetics: from past, to present, to future
por: Bettens, Karolien, et al.
Publicado: (2010)

Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?
por: Struyfs, Hanne, et al.
Publicado: (2015)

The genetic landscape of Alzheimer disease: clinical implications and perspectives
por: Van Cauwenberghe, Caroline, et al.
Publicado: (2016)

The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics
por: De Roeck, Arne, et al.
Publicado: (2019)

Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk
por: Bettens, Karolien, et al.
Publicado: (2012)

Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation
por: Van den Bossche, Tobi, et al.
Publicado: (2016)

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers
por: Suárez‐Calvet, Marc, et al.
Publicado: (2016)

The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications
por: Gossye, Helena, et al.
Publicado: (2019)

Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project
por: Roberto, Giuseppe, et al.
Publicado: (2016)

Lack of association between bridging integrator 1 (BIN1) rs744373 polymorphism and tau‐PET load in cognitively intact older adults
por: Schaeverbeke, Jolien, et al.
Publicado: (2022)

Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers()
por: Adamczuk, Katarzyna, et al.
Publicado: (2013)

Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β′-site increases Aβ generation†
por: Zhou, Lujia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_jg2f82d9mdvmf7doselrlaent7